MDGL Stock Soars 11% on New Patent Protecting Rezdiffra Dosing Rights

Key Takeaways MDGL rose 10.9% as a new U.S. patent is set to protect Rezdiffra's FDA-approved dosing regimen. The patent, valid through 2044, will be listed in the FDA's Orange Book, blocking generic competition. Over 17,000 patients are already on Rezdiffra as MDGL expands clinical data to support full approval.Madrigal Pharmaceuticals (MDGL) shares soared 10.9% on Wednesday. The uptrend was observed after the U.S. Patent and Trademark Office issued a Notice of Allowance for a new U.S. patent related to ...